Početna › Makularna degeneracija › Illinois
Kliničke studije za Makularna degeneracija u državi Illinois
13 studija za Makularna degeneracija traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
Službeni tekst studije (engleski)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- Illinois Retina Associates, Oak Park
- Springfield Clinic, Springfield
U tijeku regrutacijaFaza 2/3
Od 50 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07440225A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- University Retina, Lemont
U tijeku regrutacijaFaza 2/3
Od 60 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06635148A Study in Adults With Geographic Atrophy
- University Retina and Macula Associates, P.C., Lemont
U tijeku regrutacijaFaza 2
Od 60 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07606365A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- University of Illinois at Chicago, Chicago
- Retinal Vitreal Consultants, Chicago
- The University of Chicago, Chicago
- i još 3
U tijeku regrutacijaFaza 3
Od 50 do 85 godina · Oba spola · Ažurirano 18. ruj 2026. · NCT06541704Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Northwestern Medical Group, Chicago
- The University of Chicago Medicine Duchossois Center for Advanced Medicine, Chicago
- Retina Associates, Ltd., Elmhurst
- i još 1
U tijeku regrutacijaFaza 2
Od 55 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT06659445A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- University Retina and Macula Associates, Oak Forest
U tijeku regrutacijaFaza 1
Od 50 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT03178149A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
- University Retina and Macula Associates, Oak Forest
U tijeku regrutacijaOpažajna studija
Od 55 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07144137Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
- University Retina & Macula Associates, Lemont
U tijeku regrutacija
Od 60 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT06662162A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
- University of Illinois Chicago - UI Health, Chicago
U tijeku regrutacijaOpažajna studija
Od 6 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT074255744D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- University Retina and Macula Associates, Oak Forest
U tijeku regrutacijaFaza 1/2
Od 50 godina i više · Oba spola · Ažurirano 21. kol 2026. · NCT05197270A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- Illinois Retina Associates, Joliet
- University Retina & Macula Associates, P.C., Lemont
U tijeku regrutacijaFaza 2/3
Od 50 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07496567Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
- Adverum site 179, Lemont
U tijeku regrutacijaFaza 2
Od 50 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT07630649Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Retina Associates, Ltd., Elmhurst
- University Retina and Macula Associates, PC, Oak Forest
- Illinois Retina Associates, Oak Park
- i još 1
U tijeku regrutacijaFaza 3
Od 50 godina i više · Oba spola · Ažurirano 16. tra 2026. · NCT07064759Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.